Registration and Refreshment
"Inno has been conceptualized as a ‘one-of-its-kind’ forum which will provide a great platform for India’s budding scientists in the Pharma and Biotech space to widen their scientific horizon through interacting with global scientific thought leaders as well as give them an opportunity to showcase their research by presenting posters. The first event in this annual conference series, Inno 2018, will be a two-day Antibody Symposium which will be held in Bengaluru on 3rd and 4th December, 2018. This event will help promote innovation, facilitate knowledge sharing of cutting-edge technologies and provide an excellent opportunity to interface with distinguished international speakers. It is my privilege to invite you to be a part of this exciting event."
- Jayashree Aiyar, Chair of the Symposium
(Vice President - Discovery Biology, Syngene International Ltd.)
With over three decades of R&D experience, Philip's journey with Amgen Inc. since 1998 has seen him grow through the ranks. He currently holds responsibility for biologics discovery, medicinal, oligonucleotide and peptide chemistry; protein conjugates (ADC, peptibodies) and reagents, amongst others.
Dr. Sidhu is highly regarded for his research in the field of protein engineering and technologies exploring protein and antibody structure and function. He is a recipient of the 2015 Christian B. Anfinsen Award of the Protein Society and has authored more than 200 scientific papers and is a co-inventor of more than 50 patents granted or filed with the US patent office.
Chadwick King heads the international research team of scientists based in Burnaby, Canada, Thousand Oaks, California and Bengaluru, India. The team focuses on the discovery of novel antibodies in support of Amgen Inc.’s Therapeutic molecule pipeline and non-therapeutic antibody tools to support a wide range of drug discovery activities at various stages of development and commercialization; Discovery research, Safety Sciences, PKDM and Biomarker Discovery.
An eight-year stay at Thermo Fisher Scientific has seen Deepa rise to the role of Director R&D, where she currently oversees the research undertaken on the quality of available in-house antibodies through stringent validation programs at the Bengaluru site. Her team has been instrumental in establishing Invitrogen™ ABfinity™ and novel Superclonal™ technologies to produce recombinant, sequence-verified, sensitive affinity reagents.
Ralf Guenther is the Associate Director - Department of Protein Engineering and
Antibody Technologies at Merck KGaA in Darmstadt, Germany. He started as a
bench scientist in target research, followed by a short episode on aptamer
Beginning 2013, Guenther heads the Merck-Syngene collaboration.
Dr. Abhishek Mathur has extensive experience in product development, CMC and Regulatory Operations, and Product Commercialisation. He specialises in Applied Biology, Analytical Technologies, QbD and Biostatistics.
Sreesha Srinivasa heads the Translational Sciences Department and leading Novel Biologics Discovery and Development at Biocon Research Ltd. Sreesha obtained his Ph.D. in Molecular Cell Biology from Washington University School of Medicine, St. Louis, USA. His experience and expertise span the breadth of novel drug discovery & development of small molecules and biologics; target discovery and validation, bioassay development and screening, in vitro and in vivo pharmacology, biomarkers, companion diagnostics and clinical development. His track record includes a number of filed & granted patents, research publications, conference presentations, IND filings and two FDA approved drugs.
Andreas Menrad has overseen and helped progress NCE and NBE from bench to bedside. Over the years, he has held several senior leadership roles at ALGETA, ABLYNX, GENZYME and SCHERING AG.
Irina Rybina earned her Ph.D. in Biochemistry and Enzymology from Moscow State University, and
has a post-doctoral research fellowship from Columbia University, New York. She has headed various
research laboratories at Cambrex Inc. and Boehringer Ingelheim Inc.
Currently, Irina leads a team in the Biotherapeutics Department, in-charge of delivering challenging- to-produce proteins expressed primarily in mammalian expression systems to support the entire NBE portfolio across multiple OPUs.
Dr. Dinakar M. Salunke founded and led the Regional Centre for Biotechnology from 2009-2015,
before taking over as Director of the International Centre for Genetic Engineering & Biotechnology
(ICGEB), New Delhi.
A winner of many prestigious awards, Dr. Salunke’s primary research interests covers the structural biology of immune recognition. His work provides fundamental insights into understanding the body's defence against infections.
Kas holds a Ph.D. in Biomedical Engineering from Johns Hopkins University, Baltimore and M.S. in Chemical Engineering from the State University of New York College, Buffalo. His interest lies in the field of ADMET modelling and molecule design using machine learning and systems biology techniques.
Maloy is an expert in the field of cancer biology and biomarker development, and a member of the founding team at Zumutor Biologics. He currently leads multiple R&D programs that create novel next-generation monoclonal antibody therapeutics through Zumutor’s antibody platforms.
Kevin Harvey leads the strategic road mapping for antibody and immunoassay platforms and is the Bioscience Division task force leader for Precision Medicine at Thermo Fisher Scientific. Prior to joining Thermo Fisher, Kevin led business development, R&D, and bio- and cheminformatics teams at Affymetrix and EMD Millipore (Merck KGaA).
Dr. Saurabh is an associate director in the department of Discovery Biology at Syngene International Ltd. He joined the organisation in 2008 after doing post-doctoral research at National Institutes of Health. His current research interests include the development of novel immunisation methodologies and immunogen designs for achieving the desired immune response in the animals. His other areas of interests include designing novel platforms for bispecific antibodies. He has published several research articles in reputed journals and is co-inventor on a patent granted or filed with the US patent office. He had received several organisational awards for developing a business portfolio in the field of antibody discovery and development.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Syngene International, an innovation-focused global discovery, development and manufacturing organisation provides integrated services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemicals industries across the world. Its innovative culture is driven by a strong team of over 3500 scientists working with clients around the globe to improve R&D productivity while reducing development time and cost.
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.
41/3, MG Road, Yellappa Garden, Yellappa Chetty Layout, Sivanchetti Gardens, Bengaluru, Karnataka 560001
Phone: 080-666 04444